176 related articles for article (PubMed ID: 2456743)
1. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
Jäger W; Adam R; Wildt L; Lang N
Arch Gynecol Obstet; 1988; 243(2):91-9. PubMed ID: 2456743
[TBL] [Abstract][Full Text] [Related]
2. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
Meden H; Rath W; Teichmann A; Kuhn W
Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serial CA 125 antigen levels in ovarian cancer evaluated by second-look laparotomy.
Khoo SK; Hurst T; Webb MJ; Dickie GJ; Kearsley JH; Mackay EV
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):765-71. PubMed ID: 3477461
[TBL] [Abstract][Full Text] [Related]
4. CA 125 surveillance and second-look laparotomy in ovarian carcinoma.
Atack DB; Nisker JA; Allen HH; Tustanoff ER; Levin L
Am J Obstet Gynecol; 1986 Feb; 154(2):287-9. PubMed ID: 3456202
[TBL] [Abstract][Full Text] [Related]
5. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer.
Niloff JM; Knapp RC; Lavin PT; Malkasian GD; Berek JS; Mortel R; Whitney C; Zurawski VR; Bast RC
Am J Obstet Gynecol; 1986 Jul; 155(1):56-60. PubMed ID: 3460341
[TBL] [Abstract][Full Text] [Related]
6. [The value of preoperative diagnosis before second-look laparotomy in ovarian cancer].
Meden H; Rath W; Ohlmeyer D
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):101-5. PubMed ID: 2180783
[TBL] [Abstract][Full Text] [Related]
7. CA 125 in gynecologic practice.
Malkasian GD; Podratz KC; Stanhope CR; Ritts RE; Zurawski VR
Am J Obstet Gynecol; 1986 Sep; 155(3):515-8. PubMed ID: 2428248
[TBL] [Abstract][Full Text] [Related]
8. CA-125 in gynecological malignancies.
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):713-7. PubMed ID: 2443359
[TBL] [Abstract][Full Text] [Related]
9. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
10. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer].
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078
[TBL] [Abstract][Full Text] [Related]
11. CA125 as a serum marker for poor prognosis in ovarian malignancies.
Alvarez RD; To A; Boots LR; Shingleton HM; Hatch KD; Hubbard J; Soong SJ; Potter ME
Gynecol Oncol; 1987 Mar; 26(3):284-9. PubMed ID: 2435619
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.
Markowska J; Wilkoszarska J; Emerich J; Debniak J; Popiela A; Pańszczak M; Kornafel J; Rossochacka B; Fisher Z; Goluda M; Małecki P
Eur J Gynaecol Oncol; 2000; 21(2):164-7. PubMed ID: 10843477
[TBL] [Abstract][Full Text] [Related]
13. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of CA-125 levels in advanced ovarian cancer.
Patsner B; Day TG
Am J Obstet Gynecol; 1987 Feb; 156(2):440-1. PubMed ID: 3469916
[TBL] [Abstract][Full Text] [Related]
15. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
16. Comparison of serum CA-125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive ovarian adenocarcinoma.
Patsner B; Mann WJ; Vissicchio M; Loesch M
Gynecol Oncol; 1988 May; 30(1):98-103. PubMed ID: 2452774
[TBL] [Abstract][Full Text] [Related]
17. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
Selman AE; Copeland LJ
Curr Oncol Rep; 1999 Sep; 1(1):71-6. PubMed ID: 11122801
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma.
Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H
Gynecol Oncol; 1989 Oct; 35(1):44-6. PubMed ID: 2792900
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer.
Niloff JM; Bast RC; Schaetzl EM; Knapp RC
Am J Obstet Gynecol; 1985 Apr; 151(7):981-6. PubMed ID: 3157319
[TBL] [Abstract][Full Text] [Related]
20. CA 15-3 serum levels in ovarian cancer.
Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S
Oncology; 1988; 45(3):263-7. PubMed ID: 3163419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
